AtaiBeckley Inc. (NASDAQ: ATAI) reported that its experimental depression treatment BPL-003 achieved a 66.7% response rate by day two following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE